Industry Experts

Shuji Sato holds a PhD from Tufts University in Massachusetts and completed his postdoctoral training at the New England Primate Research Center, Harvard Medical School. Prior to joining IPA, he previously worked other biotech & pharma companies, including Cell Signaling Technology and Pfizer, and most recently, he held the position of Associate Director, Antibody Discovery with Dragonfly Therapeutics.